Efficacy of adjuvant chemotherapy according to hormone receptor status in young patients with breast cancer: A pooled analysis

Breast Cancer Research

Volumn 9, Issue 5, 2007, Pages

  van der Hage, Jos A ^a,b   Mieog, J ^a   van de Vijver, Marc J ^c   van de Velde, Cornelis J H ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b European Organization for Research   (Belgium)

^c NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; PROGESTERONE RECEPTOR; TAMOXIFEN; ANTINEOPLASTIC AGENT;

ADULT; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG RESPONSE; FEMALE; HAZARD RATIO; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MASTECTOMY; METASTASIS; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PROGNOSIS; SURVIVAL RATE; TREATMENT DURATION; TREATMENT OUTCOME; ADJUVANT CHEMOTHERAPY; BREAST TUMOR; METABOLISM; NEOPLASM; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; NEOPLASMS, HORMONE-DEPENDENT; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 36549059123     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr1778     Document Type: Article

References (24)

1. Early Breast Cancer Trialists' Collaborative Group Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials Lancet 2005, 365:1687-1717. 10.1016/S0140-6736(05)66544-0 15894097
2. Hankey BF Miller B Curtis R Kosary C Trends in breast cancer in younger women in contrast to older women J Natl Cancer Inst Monogr 1994, 16:7-14. 7999473
3. Goldhirsch A Glick JH Gelber RD Coates AS Senn HJ Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer J Clin Oncol 2001, 19:3817-3827. 11559719
4. Elkhuizen PH van Slooten HJ Clahsen PC Hermans J van de Velde CJH van den Broek LC van de Vijver MJ High local recurrence risk after breast-conserving therapy in node-negative premenopausal breast cancer patients is greatly reduced by one course of perioperative chemotherapy: a European Organization for Research and Treatment of Cancer Breast Cancer Cooperative Group Study J Clin Oncol 2000, 18:1075-1083. 10694560
5. Aebi S Gelber S Castiglione-Gertsch M Gelber RD Collins J Thurlimann B Rudenstam CM Lindtner J Crivellari D Cortes-Funes H Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer? Lancet 2000, 355L:1869-1874. 10.1016/S0140-6736(00)02292-3
6. van Dongen JA Voogd AC Fentiman IS Legrand C Sylvester RJ Tong D van der Schueren E Helle PA van Zyl K Bartelink H Long-term results of a randomized trial comparing breast-conserving therapy with mastectomy: European Organization for Research and Treatment of Cancer 10801 trial J Natl Cancer Inst 2000, 92:1143-1150. 10.1093/jnci/92.14.1143 10904087
7. van der Hage JA van De Velde CJ Julien JP Floiras JL Delozier T Vandervelden C Duchateau L Improved survival after one course of perioperative chemotherapy in early breast cancer patients: Long-term results from the European Organization for Research and Treatment of Cancer (EORTC) Trial 10854 Eur J Cancer 2001, 37:2184-2193. 10.1016/ S0959-8049(01)00294-5 11677105
8. van der Hage JA van de Velde CJ Julien JP Tubiana-Hulin M Vandervelden C Duchateau L Preoperative chemotherapy in primary operable breast cancer: results from the European organization for research and treatment of cancer trial 10902 J Clin Oncol 2001, 19:4224-4237. 11709566
9. Bartelink H Horiot JC Poortmans P Struikmans H Van den Bogaert W Barillot I Fourquet A Borger J Jager J Hoogenraad W European Organization for Research and Treatment of Cancer Radiotherapy and Breast Cancer Groups: Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation N Engl J Med 2001, 345:1378-1387. 10.1056/NEJMoa010874 11794170
10. Bloom HJG Richardson WW Histological grading and prognosis in breast cancer: A study of 1409 cases of which 359 have been followed for 15 years Br J Cancer 1957, 11:359-377. 13499785
11. Bubendorf L Nocito A Moch H Sauter G Tissue microarray (TMA) technology: miniaturized pathology archives for high-throughput in situ studies J Pathol 2001, 195:72-79. 10.1002/path.893 11568893
12. Hoos A Urist MJ Stojadinovic A Mastorides S Dudas ME Leung DH Kuo D Brennan MF Lewis JJ Cordon-Cardo C Validation of tissue microarrays for immunohistochemical profiling of cancer specimens using the example of human fibroblastic tumors Am J Pathol 2001, 158:1245-1251. 1891917 11290542
13. Mueller-Holzner E Fink V Frede T Marth C Immunohistochemical determination of HER2 expression in breast cancer from core biopsy specimens: A reliable predictor of HER2 status of the whole tumor Breast Cancer Res Treat 2001, 69:13-19. 10.1023/A:1012281221647 11759824
14. Kallioniemi OP Wagner U Kononen J Sauter G Tissue microarray technology for high-throughput molecular profiling of cancer Hum Mol Genet 2001, 10:657-662. 10.1093/hmg/10.7.657 11257096
15. Kaplan EL Meier P Nonparametric estimation from incomplete observations J Am Stat Assoc 1958, 53:457-481. 10.2307/2281868
16. Cox DR Regression models and life-tables J R Stat Assoc [B] 1972, 34:187-220.
17. Viale G Gelber RD Mastropasqua MG Maiorano E Aldrighetto S Price KN Castiglione-Gertsch M Goldhirsch A Chemo-endocrine effects of adjuvant therapies for postmenopausal node-negative breast cancer according to ER, PgR, and Her2 assessed centrally Breast Cancer Res Treat 2003, 82S:S16-S17.
18. Albain K Barlow W O'Malley F Siziopikou K Yeh I-T Ravdin P Lew D Farrar W Burton G Ketchel S for the Breast Cancer Intergroup of North America Concurrent (CAFT) versus sequential (CAF-T) chemohormonal therapy (cyclophosphamide, doxorubicin, 5-fluorouracil, tamoxifen) versus T alone for postmenopausal, node-positive, estrogen (ER) and/or progesterone (PgR) receptor-positive breast cancer: Mature outcomes and new biologic correlates on phase III intergroup trial 0100 (SWOG-8814) Breast Cancer Res Treat 2004, 88S: Abstract 37.
19. Ring AE Smith IE Ashley S Fulford LG Lakhani SR Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer Br J Cancer 2004, 91:2012-2017. 10.1038/sj.bjc.6602235 15558072
20. Colleoni M Viale G Zahrieh D Pruneri G Gentilini O Veronesi P Gelber RD Curigliano G Torrisi R Luini A Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: A study of preoperative treatment Clin Cancer Res 2004, 10:6622-6628. 10.1158/1078-0432.CCR-04-0380 15475452
21. Kuerer HM Newman LA Smith TL Ames FC Hunt KK Dhingra K Theriault RL Singh G Binkley SM Sneige N Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy J Clin Oncol 1999, 17:460-469. 10080586
22. LHRH-agonists in Early Breast Cancer Overview group Cuzick J Ambroisine L Davidson N Jakesz R Kaufmann M Regan M Sainsbury R Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: A meta-analysis of individual patient data from randomised adjuvant trials Lancet 2007 369 1711 1723 10.1016/S0140-6736(07)60778-8 17512856
23. Jonat W Pritchard KI Sainsbury R Klijn JG Trends in endocrine therapy and chemotherapy for early breast cancer: A focus on the premenopausal patient J Cancer Res Clin Oncol 2006, 132:275-286. 10.1007/ s00432-006-0082-z 16435142
24. Goldhirsch A Glick JH Gelber RD Coates AS Thürlimann B Senn HJ Panel members Meeting highlights: International expert consensus on the primary therapy of early breast cancer 2005 Ann Oncol 2005, 16:1569-1583. 10.1093/annonc/mdi326 16148022